



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

von BORSTEL et al

Atty. Ref.: 1331-352

Serial No. 09/930,494

TC/A.U.: 1623

Filed: August 16, 2001

Examiner: Patrick T. Lewis

For: COMPOSITIONS AND METHODS FOR TREATMENT OF
MITOCHONDRIAL DISEASES

* * * * *

January 26, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. The requisite IDS fee is attached.

The Examiner is requested to initial the attached form PTO/SB/08a and to return a copy of the initialed document to the undersigned.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lfm
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

01/27/2006 SZEWDIE1 00000082 09930494

02 FC:1806

180.00 0P

1037058


**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

1331-352

SERIAL NO.

09/930,494

APPLICANT

von BORSTEL et al

(Use several sheets if necessary)

FILING DATE

August 16, 2001

TC/A.U.

1623

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| DOCUMENT | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
|----------|------|---------|-------|----------|-----------------------|
| | | | | | |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

| | |
|--|---|
| | Saydoff <i>et al.</i> "Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease", <i>Brain Res.</i> (2003) 994(1):44-54 |
| | Gines <i>et al.</i> , "Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice", <i>Hum Mol Genet.</i> (2003);12(5):497-508 (Abstract) |
| | Lam et al (Eur J Pediatr. 1997 Jul;156(7):562-4. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Lam CW, Lau CH, Williams JC, Chan YW, Wong LJ. Department of Pathology, Princess Margaret Hospital, Lai Chi Kok, Hong Kong) |
| | Krahenbuhl et al (Liver. 2000 Jul;20(4):346-8; Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D. Department of Clinical Pharmacology, University of Berne, Switzerland) |
| | Ritchie et al., "Diagnostic Approach to Polyarticular Joint Pain", <i>American Family Physician</i> , 68, 6, 1151-1160 (2003) |
| | Page, et al., "A Syndrome of Megaloblastic Anemia, Immunodeficiency, and Excessive Nucleotide Degradation," in <i>Purine and Pyrimidine Metabolism in Man VII, Part B</i> , Harkness, et al. eds (1991) pp. 345-348 |
| | DiMauro, et al, "Mitochondrial encephalomyopathies: where next?", <i>Revista de Neurologia</i> (1999) 28(2):164-168 |
| | Luft, "Review: The development of mitochondrial medicine", <i>Proc. Natl. Acad. Sci. USA</i> (September 1994) 91: 8731-8738 |
| | Beal, "Mitochondrial dysfunction in neurodegenerative diseases", <i>Biochimica et Biophysica Acta</i> (1998) 1366: 211-223 |
| | Blass, "Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia", <i>J. Neurosc. Res.</i> (2001) 66: 851-856 |
| | Bowling, et al., "Minireview: Bioenergetic and Oxidative stress in neurodegenerative diseases", <i>Life Sciences</i> (1995) 56(14): 1151-1171 |
| | Beal, "Mitochondria, free radicals, and neurodegeneration", <i>Current Opinion Neurobiol.</i> (1996) 6: 661-666 |
| | Browne, et al, "Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases", <i>Biochem. Soc. Trans.</i> (1994) 22: 1002-1006 |
| | Schulz, et al., "Mitochondrial dysfunction in movement disorders", <i>Current Opinion in Neurology</i> (1994) 7:333-339 |

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet 2 of 1

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

1331-352

APPLICANT

von BORSTEL et al

FILING DATE

August 16, 2001


SERIAL NO.

09/930,494

TC/A.U.

1623

(Use several sheets if necessary)



*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.